Tarsus Pharmaceuticals, Inc. TARS Lease Liability Payments - Due Year Three
Lease Liability Payments - Due Year Three at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s lease liability payments - due year three.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s lease liability payments - due year three?
- Tarsus Pharmaceuticals, Inc. (TARS) reported lease liability payments - due year three of $2.78M in Q1 2026.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s lease liability payments - due year three?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s lease liability payments - due year three has grown at a 57.3% compound annual growth rate (CAGR), from $281K to $2.7M.
- What does lease liability payments - due year three mean?
- The contractual cash obligations for operating and finance leases due in the third year following the balance sheet date. This metric helps in mapping out the long-term fixed cost profile of the company. It is essential for evaluating the sustainability of lease-related cash outflows over a multi-year horizon.